Alpha 2.0
Login Register
» Articles » PMID: 38994340

From Psoriasis to Psoriatic Arthritis: Epidemiological Insights from a Retrospective Cohort Study of 74,046 Patients

Overview
Journal Front Med (Lausanne)
Specialty General Medicine
Date 2024 Jul 12
PMID 38994340
Authors
An-Ping Huo
Pei-Lun Liao
Pui-Ying Leong
James Cheng-Chung Wei
Affiliations
Soon will be listed here.
Abstract

Introduction: To verify our hypothesis that psoriatic arthritis (PsA) is mainly genetically predetermined and distinct from psoriasis (PsO), we use the TriNetX database to investigate whether intrinsic factors outweigh externals in PsA emergence in PsO patients.

Methods: We conducted three retrospective cohort studies utilizing information from the TriNetX network, whether (a) PsO patients with type 2 diabetes mellitus (DM) face an elevated risk of developing PsA compared to those without type 2 DM; (b) PsO patients who smoke face a higher risk of PsA; and (c) PsO patients with type 2 DM who smoke are more likely to develop PsA than those who do not smoke.

Results: PsO patients with type 2 DM exhibited an elevated risk of developing PsA [hazard ratio (HR), 1.11; 95% CI 1.03-1.20], with the combined outcome demonstrating a heightened HR of 1.31 (95% CI 1.25-1.37). PsO patients with a smoking history exhibited an elevated risk of developing PsA (HR, 1.11; 95% CI 1.06-1.17), with the combined outcome demonstrating a heightened HR of 1.28 (95% CI 1.24-1.33). PsO patients with type 2 DM and a history of smoking were not found to be associated with an increased risk of developing PsA (HR, 1.05; 95% CI 0.92-1.20). However, the combined result revealed a higher risk of 1.15 (95% CI 1.06).

Discussion: These findings suggested that intrinsic factors outweigh external factors in PsA emergence in PsO patients. Further studies may focus on genetic disparities between PsO and PsA as potential risk indicators rather than solely on phenotypic distinctions.

References
1.
Mulder M, van Hal T, Wenink M, Koenen H, van den Hoogen F, de Jong E . Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review. Arthritis Res Ther. 2021; 23(1):168. PMC: 8201808. DOI: 10.1186/s13075-021-02545-4. View
2.
Asahina A, Umezawa Y, Momose M, Honda H, Yanaba K, Nakagawa H . New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study. J Dermatol. 2017; 44(12):1380-1384. DOI: 10.1111/1346-8138.13987. View
3.
Zabotti A, De Lucia O, Sakellariou G, Batticciotto A, Cincinelli G, Giovannini I . Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. Rheumatol Ther. 2021; 8(4):1519-1534. PMC: 8572278. DOI: 10.1007/s40744-021-00378-w. View
4.
Wang W, Wang C, Wang S, Cheng-Chung Wei J . Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022; 53:101619. PMC: 9366236. DOI: 10.1016/j.eclinm.2022.101619. View
5.
Meer E, Merola J, Fitzsimmons R, Love T, Wang S, Shin D . Does biologic therapy impact the development of PsA among patients with psoriasis?. Ann Rheum Dis. 2021; 81(1):80-86. DOI: 10.1136/annrheumdis-2021-220761. View